| Trial ID: | L0796 |
| Source ID: | NCT04392206
|
| Associated Drug: |
Adipose Derived Mesenchymal Stem Cells
|
| Title: |
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease
|
| Interventions: |
DRUG: Adipose Derived Mesenchymal Stem Cells
|
| Outcome Measures: |
Primary: Number of participants with treatment-related adverse events, Evaluate the safety of AMSC administration by assessing the number of participants to experience an adverse event as defined by inflammation, infection (local or systemic), aneurysm formation, clinically significant increase or decrease in blood flow or thrombosis formation as evaluated through physical exam and ultrasound., 12 months |
|
| Sponsor/Collaborators: |
Sponsor: Houssam Farres, M.D.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-05-15
|
| Completion Date: |
2025-06
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-09
|
| Locations: |
Mayo Clinic in Florida, Jacksonville, Florida, 32224, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04392206
|
